Cargando…
Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients
BACKGROUND: This study investigated the risk of prostate cancer in ever users and never users of rosiglitazone in diabetes patients in Taiwan. METHODS: The nationwide database of the National Health Insurance was used to enroll male patients who had a new diagnosis of type 2 diabetes mellitus at an...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407244/ https://www.ncbi.nlm.nih.gov/pubmed/37560306 http://dx.doi.org/10.3389/fendo.2023.1185053 |